dc.contributor.author | Watson, Martin Matthew Christian | |
dc.contributor.author | Lea, Dordi | |
dc.contributor.author | Gudlaugsson, Einar | |
dc.contributor.author | Skaland, Ivar | |
dc.contributor.author | Hagland, Hanne Røland | |
dc.contributor.author | Søreide, Kjetil | |
dc.date.accessioned | 2021-05-08T19:55:39Z | |
dc.date.available | 2021-05-08T19:55:39Z | |
dc.date.created | 2020-11-12T08:09:19Z | |
dc.date.issued | 2020-08 | |
dc.identifier.citation | Watson, M.M., Lea, D., Gudlaugsson, E. et al. (2020) Cancer Immunology and Immunotherapy, 69(8), 1627-1637. | en_US |
dc.identifier.issn | 0340-7004 | |
dc.identifier.uri | https://hdl.handle.net/11250/2754450 | |
dc.description.abstract | Introduction
Microsatellite instability (MSI) predict response to anti-PD1 immunotherapy in colorectal cancer (CRC). CRCs with MSI have higher infiltration of immune cells related to a better survival. Elevated Microsatellite Alterations at Tetranucleotides (EMAST) is a form of MSI but its association with PD-L1 expression and immune-cell infiltration is not known.
Methods
A consecutive, observational cohort of patients undergoing surgery for CRC. EMAST and clinicopathological characteristics were investigated against PD-L1, as well as CD3 and CD8 expression in the invasive margin or tumour centre (Immunoscore). Difference in survival between groups was assessed by log rank test.
Results
A total of 149 stage I–III CRCs patients, with a median follow up of 60.1 months. Patients with PD-L1+ tumours (7%) were older (median 79 vs 71 years, p = 0.045) and had EMAST+ cancers (OR 10.7, 95% CI 2.2–51.4, p = 0.001). Recurrence-free survival was longer in cancers with PD-L1+ immune cells (HR 0.35, 95% CI 0.16–0.76, p = 0.008, independent of EMAST) and high Immunoscore (HR 0.10, 95% CI 0.01–0.72, p = 0.022). Patients expressing PD-L1 in immune cells had longer disease-specific survival (HR 0.28, 95% CI 0.10–0.77, p = 0.014).
Conclusions
Higher Immunoscore (CD3/CD8 cells) and expression of tumour PD-L1 is found in CRCs with EMAST. Lymphocytic infiltrate and peritumoral PD-L1 expression have prognostic value in CRC. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer Nature Switzerland AG | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.subject | tarmkreft | en_US |
dc.subject | colorectal cancer | en_US |
dc.subject | kreft | en_US |
dc.title | Prevalence of PD‑L1 expression is associated with EMAST, density of peritumoral T‑cells and recurrence‑free survival in operable non‑metastatic colorectal cancer | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | © The Author(s) 2020 | en_US |
dc.subject.nsi | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762 | en_US |
dc.source.pagenumber | 1627-1637 | en_US |
dc.source.volume | 69 | en_US |
dc.source.journal | Cancer Immunology and Immunotherapy | en_US |
dc.source.issue | 8 | en_US |
dc.identifier.doi | 10.1007/s0026 2-020-02573 -0) | |
dc.identifier.cristin | 1847200 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |